

GLAXOSMITHKLINE PLC  
Form 6-K  
October 09, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending October 2013

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging  
Managerial Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline 2009 Performance Share Plan notified the Company and the under-mentioned persons on 8 October 2013 of the following increases in their notional interests in Ordinary Shares at a price of 1571 pence per Ordinary Share and American Depositary Shares (ADSs) at a price of \$50.84 per ADS following the notional re-investment of the dividend paid to shareholders on 3 October 2013.

	Ordinary Shares	ADSs
Sir Andrew Witty	17,855.571	
Dr M M Slaoui		5,353.520
Mr S Dingemans	6,924.754	
Mr S M Bicknell	1,873.095	
Mr R G Connor	1,241.889	
Mrs D P Connelly		2,258.480
Mr S A Hussain	5,449.411	
Mr W C Louv		1,559.989
Mr D S Redfern	2,675.845	
Ms C Thomas	3,719.017	
Mr P C Thomson	1,180.887	
Mr D E Troy		3,008.734
	6,159.639	

Dr P J T  
Vallance

Ms E 3,497.511  
Walmsley

Mr C 872.878  
Weber

Mrs V A 438.511  
Whyte

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant measurement period.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell  
Company Secretary

9 October 2013

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 09, 2013

By: SIMON BICKNELL  
-----

Simon Bicknell  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc